RxDoctor Payments Data

Berneet Kaur, MD

Neurology · Chattanooga, TNNPI 1477729002

Payments from drug & device makers

$26,513in general payments, 2019–2025

Across 237 payments — averaging $111.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eisai Inc.$23K
  • Teva Pharmaceuticals USA, Inc.$545
  • Lilly USA, LLC$453
  • Otsuka America Pharmaceutical, Inc.$452
  • AbbVie$278
  • Neurelis, Inc.$176
  • plus $2K from 37 others

What the payments were for

  • Consulting fees$4,74318%
  • Speaking & faculty fees$15,40358%
  • Travel & lodging$1,2245%
  • Food & beverage$5,10019%
  • Education$430%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$26,513 in reported general payments places this provider in the 75th percentile of 361 neurology providers in Tennessee.

See all neurology providers in Tennessee

Medicare billing

Part B allowed, 2024
$106,716
Medicare patients
339
Services billed
930

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole28$39,585
Rivastigmine12$5,702
Memantine Hcl177$4,650
Lacosamide21$4,357
Levetiracetam83$4,131
Galantamine ErGalantamine Hbr31$2,963
Donepezil Hcl298$2,885
Escitalopram Oxalate192$1,906
Mirtazapine57$1,344
Sertraline Hcl171$1,100
Carbidopa-LevodopaCarbidopa/Levodopa65$1,092
Duloxetine Hcl55$1,070
RivastigmineRivastigmine Tartrate12$1,062
Trazodone Hcl132$878
Gabapentin60$817

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti$452$39,58528 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 361 neurology providers in Tennessee.

Other neurology in Chattanooga

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →